Samuel D. Rabkin

Molecular Neurosurgery Laboratory and the Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School

Affiliated withMassachusetts General Hospital and Harvard Medical School

Research Area

Immunology and Infection

Biography

Samuel D. Rabkin has not added Biography.
If you are Samuel D. Rabkin and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 6	2021

Other Publications

Article	Year
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer gene therapy\| PubMed ID: 12522436	2002
Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer research\| PubMed ID: 15735042	2005
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 17045531	2006
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17121900	2006
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17908985	2007
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 18388912	2008
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer research\| PubMed ID: 20424118	2010
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21505062	2011
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21976549	2011
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. Journal of the National Cancer Institute\| PubMed ID: 22173583	2012
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. Journal of virology\| PubMed ID: 22345479	2012
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem cells translational medicine\| PubMed ID: 23197811	2012
Current status of gene therapy for brain tumors. Translational research : the journal of laboratory and clinical medicine\| PubMed ID: 23246627	2013
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell reports\| PubMed ID: 23707066	2013
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 23754388	2013
Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro-oncology\| PubMed ID: 24470552	2014
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell\| PubMed ID: 24726434	2014
Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta. Cancer cell international\| PubMed ID: 25360068	2014
Designing Herpes Viruses as Oncolytics. Molecular therapy oncolytics\| PubMed ID: 26462293	2015
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs of the future\| PubMed ID: 26855472	2015
Oncolytic herpes simplex virus interactions with the host immune system. Current opinion in virology\| PubMed ID: 27497296	2016
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer cell\| PubMed ID: 28810147	2017
Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade. Oncoscience\| PubMed ID: 28966936	2017
Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells. Journal of virology\| PubMed ID: 29793956	2018
Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Molecular therapy oncolytics\| PubMed ID: 31016228	2019
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology\| PubMed ID: 31143509	2019
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nature communications\| PubMed ID: 31266951	2019
Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta neuropathologica communications\| PubMed ID: 33308315	2020